CELC
Celcuity Inc.
NASDAQ · Healthcare · Biotechnology · US
$57.12
+0.95%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$58.19
From 52W high−60.60%
Volume2.57M
Market cap$2.79B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$58.19
From 52W high
−60.60%
Volume
2.57M
Market cap
$2.79B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−15.1x
P/E (TTM)
—
RSI (14)
25.7
MomentumView details →
1D Return
+0.95%
YTD Return
−41.72%
SummaryUpdated Jun 1, 2026
Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company founded in 2011 and headquartered in Minneapolis, Minnesota. The company went public in September 2017 and focuses on developing molecularly targeted cancer therapies. Celcuity operates through two main platforms: its lead drug candidate <b>gedatolisib</b>, which targets multiple cancer pathways simultaneously, and its proprietary <b>CELsignia diagnostic platform</b> that uses living tumor cells to identify specific cellular processes driving individual patients' cancers. The company is currently in late-stage clinical trials with potential regulatory approval on the horizon for 2025-2026.
Similar companies
Latest newsMore news →
Celcuity Inc. announced that a late-breaking rapid oral presentation and three poster presentations on its gedatolisib clinical trial data will be featured at the ESMO Congress 2026, to be held October 23-27, 2026, in Madrid, Spain.15d agoCelcuity Inc. appointed David W. Gryska as a director effective October 1, 2026, with an annual base salary of $70,000 and a pro-rated grant of 893 restricted stock units.18d ago